The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody-drug conjugate for the treatment of newly diagnosed acute myeloid leukemia.

Egan, Pamela C; Reagan, John L

Egan, Pamela C; Reagan, John L.

Afiliación

Egan PC; Division of Hematology and Oncology, Rhode Island Hospital, The Alpert Medical School of Brown University, Providence, RI, USA, john_reagan@brown.edu.
Reagan JL; Division of Hematology and Oncology, Rhode Island Hospital, The Alpert Medical School of Brown University, Providence, RI, USA, john_reagan@brown.edu.

Onco Targets Ther ; 11: 8265-8272, 2018.

Article en En | MEDLINE | ID: mdl-30538495

Palabras clave

AML; core binding factor; leukemia; treatment

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Onco Targets Ther Año: 2018 Tipo del documento: Article Pais de publicación: Nueva Zelanda

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google